NASDAQ:ZBIO

Zenas BioPharma Q1 2025 Earnings Results & Report

Zenas BioPharma logo
$27.93 -0.08 (-0.29%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$27.94 +0.02 (+0.05%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.80 versus the -$1.15 consensus estimate, while revenue of $10 million topped the $5 million estimate by $5 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Zenas BioPharma EPS Results

Actual EPS
-$0.80
Consensus EPS
-$1.15
Beat/Miss
Beat by +$0.35
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Zenas BioPharma Revenue Results

Actual Revenue
$10 million
Expected Revenue
$5 million
Beat/Miss
Beat by +$5.00 million
YoY Revenue Growth
N/A

Upcoming Earnings

Zenas BioPharma's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Zenas BioPharma Q1 2025 Earnings FAQ

Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$0.80 per share for Q1 2025, beating the consensus estimate of -$1.15. The report was announced on Thursday, May 15, 2025.

Zenas BioPharma reported revenue of $10 million for Q1 2025, against a consensus estimate of $5 million.

Zenas BioPharma's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zenas BioPharma on the company's earnings history page.

Zenas BioPharma Earnings Headlines

FY2026 EPS Forecast for Zenas BioPharma Decreased by Analyst
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.

Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.

The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.

View Zenas BioPharma Profile